{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:33:41Z","timestamp":1793799221855,"version":"4.6.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.annonc.2024.08.2239","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T13:13:34Z","timestamp":1723554814000},"page":"1039-1047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"title":["Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6145-4426","authenticated-orcid":false,"given":"T.M.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8437-2797","authenticated-orcid":false,"given":"M.","family":"Taszner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8750-0195","authenticated-orcid":false,"given":"S.","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S-G.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Villasboas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Merli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jim\u00e9nez-Ubieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-3329","authenticated-orcid":false,"given":"B.","family":"Tessoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Walewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Guidez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Jagadeesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Magnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Iskierka-Ja\u017cd\u017cewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-4260","authenticated-orcid":false,"given":"B.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Uppala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5669-9602","authenticated-orcid":false,"given":"M.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Shariff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3839-6791","authenticated-orcid":false,"given":"J.","family":"Brouwer-Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ambati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8446-2285","authenticated-orcid":false,"given":"S.","family":"Luminari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.annonc.2024.08.2239_bib2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/ejh.13271","article-title":"Diagnosis and management of follicular lymphoma: a comprehensive review","volume":"103","author":"Dada","year":"2019","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.annonc.2024.08.2239_bib3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.annonc.2024.08.2239_bib4","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3324\/haematol.2022.281421","article-title":"Treatment patterns and outcomes in relapsed\/refractory follicular lymphoma: results from the international SCHOLAR-5 study","volume":"108","author":"Ghione","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.annonc.2024.08.2239_bib5","series-title":"B-cell lymphomas","article-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae)","year":"12024"},{"issue":"3","key":"10.1016\/j.annonc.2024.08.2239_bib6","first-page":"163","article-title":"Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharmaceut Med"},{"issue":"12","key":"10.1016\/j.annonc.2024.08.2239_bib7","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor T-cell therapies: barriers and solutions to access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"10.1016\/j.annonc.2024.08.2239_bib8","first-page":"134","article-title":"Autologous and allogeneic CAR T-cell therapies: spotlighting the \u201cbrain-to-vein\u201d time","volume":"20","author":"Lunning","year":"2022","journal-title":"Clin Adv Hematol Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2024.08.2239_bib9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2024.08.2239_bib10","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.annonc.2024.08.2239_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/srep17943","article-title":"A\u00a0novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse\u00a0tumor models and cynomolgus monkeys","volume":"5","author":"Smith","year":"2015","journal-title":"Sci Rep"},{"issue":"27","key":"10.1016\/j.annonc.2024.08.2239_bib12","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"28","key":"10.1016\/j.annonc.2024.08.2239_bib13","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2024.08.2239_bib14","doi-asserted-by":"crossref","first-page":"9257","DOI":"10.1182\/blood-2022-162814","article-title":"Detection of early molecular response (EMR) and minimal residual disease (MRD) in patients with diffuse large B-cell lymphoma (DLBCL) using a validated next generation sequencing (NGS) assay for the detection of tumor variants in circulating tumor (ct)DNA","volume":"140","author":"Stokowski","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.annonc.2024.08.2239_bib15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.annonc.2024.08.2239_bib16","unstructured":"Bravo Padr\u00f3s M, Conrado DJ, Zhu M, et\u00a0al. Population pharmacokinetics of odronextamab in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma. Presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, March 27-29, 2024; Colorado Springs, CO, USA. Poster PII-067."},{"issue":"suppl 1","key":"10.1016\/j.annonc.2024.08.2239_bib17","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2023-179818","article-title":"Final analysis of the phase 2 ELM-2 study: odronextamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)","volume":"142","author":"Ayyappan","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.annonc.2024.08.2239_bib18","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2024.08.2239_bib19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.annonc.2024.08.2239_bib20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a\u00a0single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2024.08.2239_bib21","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"issue":"33","key":"10.1016\/j.annonc.2024.08.2239_bib22","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"35","key":"10.1016\/j.annonc.2024.08.2239_bib23","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.08.2239_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.annonc.2024.08.2239_bib25","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2023022348","article-title":"Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas","volume":"143","author":"Schuster","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.annonc.2024.08.2239_bib26","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41375-019-0559-9","article-title":"MRD response in relapsed\/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial","volume":"34","author":"Pott","year":"2020","journal-title":"Leukemia"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2024.08.2239_bib27","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1182\/blood-2023-179612","article-title":"Minimal residual disease (MRD) status predicts outcomes in patients with follicular lymphoma (FL) treated with chemo-immunotherapy on SWOG S0016","volume":"142","author":"Danilov","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2024.08.2239_bib28","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1182\/blood-2023-181942","article-title":"Maintenance of moderate to high levels of functioning and quality of life with odronextamab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"142","author":"Tessoulin","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.annonc.2024.08.2239_bib29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12865-022-00536-x","article-title":"Patients with indolent lymphomas are at high risk of infections: experience from a German outpatient clinic","volume":"24","author":"Lutz","year":"2023","journal-title":"BMC Immunol"},{"issue":"3","key":"10.1016\/j.annonc.2024.08.2239_bib30","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s40520-019-01375-4","article-title":"Infections in the older population: what do we know?","volume":"33","author":"Schoevaerdts","year":"2021","journal-title":"Aging Clin Exp Res"},{"issue":"2","key":"10.1016\/j.annonc.2024.08.2239_bib31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/cid\/ciy458","article-title":"Increased risk of infectious complications in older patients with indolent non-Hodgkin lymphoma exposed to bendamustine","volume":"68","author":"Fung","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2024.08.2239_bib32","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1182\/blood-2023-180675","article-title":"Odronextamab monotherapy for the treatment of relapsed\/refractory (R\/R) follicular lymphoma and diffuse large B-cell lymphoma (DLBCL): focus on clinical pharmacology and pharmacometrics in the ELM-1 and ELM-2 studies","volume":"142","author":"Zhu","year":"2023","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1016\/j.annonc.2024.11.009","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000}}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424037591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424037591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T12:14:29Z","timestamp":1732277669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753424037591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0923753424037591"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2239","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}